accepting new patients

Dr. Savage joined the Clinical Genetics Branch, DCEG, NCI in 2006 as a tenure-track investigator. She was awarded scientific tenure by the NIH and appointed senior investigator in 2012. In 2013, she was promoted to Branch Chief, and in 2018, she became the Clinical Director for DCEG. Dr. Savage received her M.D. from the University of Vermont College of Medicine, completed residency training in Pediatrics at Children’s National Medical Center, in Washington DC, and a fellowship in Pediatric Hematology/Oncology at the NCI Pediatric Oncology Branch and Johns Hopkins University. She is board

Dr. Josh Sasine is a hematologist and oncologist at UCLA specializing in the treatment of hematologic malignancies, including hematopoietic stem cell transplantation (bone marrow transplantation), cellular therapy, and clinical trials of novel therapeutics. He is the Director of the Chimeric Antigen Receptor T-Cell (CAR T) Program. He treats patients with blood and bone marrow disorders such as leukemia, myelodysplastic syndrome, lymphoma, multiple myeloma, amyloidosis, aplastic anemia, Waldenstrom Macroglobulinemia, polycythemia vera, primary myelofibrosis, paroxysmal nocturnal hemoglobinuria

Dr. David Sallman is an Assistant Member in the Department of Malignant Hematology at Moffitt Cancer Center. Dr. Sallman’s clinical interests are myelodysplastic syndromes (MDS), acute myeloid leukemia (AML) and myeloproliferative neoplasms (MPN). Dr. Sallman earned his MD degree from the University of South Florida College of Medicine. He completed an Internal Medicine Residency at Massachusetts General Hospital and, most recently, a Hematology/Oncology Fellowship at Moffitt Cancer Center. His research interests focus on the development of novel, targeted therapeutic strategies (Phase I and

Dr. Rampal is a hematology-oncology physician who specializes in the treatment of myeloproliferative neoplasms (MPN) and leukemia. He is dedicated to providing my patients with the best possible care, taking into account the individual needs of each patient and his or her family. In addition, Dr. Rampal is an active researcher whose focus is the development of new and innovative approaches to treating MPNs and leukemia. He is working to understand the genetic events that contribute to the development and progression of leukemia and MPNs in the hope of developing new targeted therapies for

After completing Internal Medicine Internship, Residency, and Hematology fellowship at Baylor College of Medicine, Dr. Rice joined the faculty and became a Professor of Medicine and Professor of Thrombosis Research. For more than 20 years, he was the Hematology Program Director and Director of the required medical student Hematology/Oncology course. In 2007, his primary affiliation changed to Chief of Hematology at Houston Methodist Hospital (HMH) and Professor of Medicine at Weill Cornell Medical College. He has maintained an active Consultative Hematology practice at HMH for 40 years. This